Drugs / Tergenpumatucel-L
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00073398 | Nov 2003 → Nov 2012 | lung adenocarcinoma, lung large cell carcinoma, squamous cell lung carcinoma | NewLink Genetics Corporation | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02460367 Background | Jan 2016 → Jul 2017 | non-small cell lung carcinoma | NewLink Genetics Corporation | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tergenpumatucel-L | “A Phase I/II Study of Tergenpumatucel-L (HyperAcute Lung) an Antitumor Vaccination Using Alpha (1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells” NCT00073398 ↗ |
| Known as | HyperAcute-Lung | “A Phase I/II Study of Tergenpumatucel-L (HyperAcute Lung) an Antitumor Vaccination Using Alpha (1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells” NCT00073398 ↗ |
| Modality | Vaccine | “antitumor vaccination” NCT00073398 ↗ |